$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)

Core Viewpoint - Monteverde & Associates PC is investigating Blueprint Medicines Corporation regarding its proposed sale to Sanofi, which involves a cash payment of $129.00 per share and contingent value rights for future milestone payments [1]. Group 1: Transaction Details - Sanofi will pay $129.00 per share in cash at closing for Blueprint Medicines Corporation [1]. - Shareholders will receive one non-tradeable contingent value right (CVR) for potential milestone payments of $2.00 and $4.00, contingent on future development and regulatory milestones for BLU-808 [1]. Group 2: Legal Firm Background - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is located in the Empire State Building in New York City and specializes in class action securities litigation [2].